I do think that anyone on HC would object at all to a TO, it's just that we have "seen" $4 previously, now since that SP we have:
1. significant increases in RoW sales
2. sales to come in India
3. Potentially positive news from the BARDA trial
4. Uses expanded (and hopefully approved) for VLU and DFU
5.A truly global CEO who dovetails very well with the chair and board members
6. A track record for use in war zones and field hospitals - given the way the world is heading, a potentially significant aspect
7. Breast and hernia products - less so than the previously mentioned points
There are many more, my point being that now that we have had a taste of a $4 SP, I assume (rightly or wrongly) that many investors would want to see a figure higher than this, as always DYOR and take care....and no this is not Fin advice!
Ann: India update, page-34
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
0.110(4.74%) |
Mkt cap ! $1.677B | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.45 | $2.38 | $2.896M | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 9997 | 4 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |